Current Environment: Production

Warning

An important message to our patients and their caregivers.

We are here for you. Read more

Summary

The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).

Conditions

Duchenne Muscular Dystrophy

Recruitment Status

TERMINATED

Eligibility Criteria

Inclusion Criteria:

* Completed a clinical trial evaluating casimersen or golodirsen, per protocol.
* Is between 7 and 23 years of age, inclusive, at enrollment.

Other inclusion/exclusion criteria apply.

Intervention

Intervention Type

Intervention Name

DRUG

Casimersen

DRUG

Golodirsen

Phase

PHASE3

Gender

MALE

Min Age

7 Years

Max Age

23 Years

Download Date

2024-09-19

Principal Investigator

N/A

Primary Contact Information

For more information on this trial, visit clinicaltrials.gov.

Contact

For more information and to contact the study team:

An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy NCT03532542